Abstract

Magnesium (Mg) is an essential element that plays pivotal roles in a number of biological processes in the human body. Hypomagnesemia is involved in the pathophysiology of hypertension, vascular calcification, and metabolic derangements including diabetes mellitus and dyslipidemia, which are all risk factors for cardiovascular disease, the leading cause of mortality and morbidity in patients with chronic kidney disease (CKD). Hypomagnesemia is also associated with the development and progression of CKD. As CKD advances, renal Mg excretion decreases and hypermagnesemia emerges in end-stage renal disease (ESRD). In addition, dialysates with high Mg concentrations, which were used in the early era of dialysis therapy, increased the risk of hypermagnesemia, and thus, the dialysate Mg composition has since been reduced. Accordingly, dialysis patients in the modern era commonly have normomagnesemia or even hypomagnesemia. The relationships between hypomagnesemia and cardiovascular disease and mortality have been increasingly reported in observational studies in CKD/ESRD. However, these relationships may be attenuated by a patient’s race or region. Although dialysates with higher Mg concentrations or Mg-containing phosphate binders appear to be promising in this setting, only a few interventional studies have examined the effects of Mg supplementation on cardiovascular lesions. Furthermore, the effects of Mg supplementation on mortality have not yet been investigated as a primary end-point in randomized controlled trials. Further studies are required in order to establish the efficacy and safety of Mg in CKD patients.

Background

Magnesium (Mg), the fourth most abundant cation in the human body, is a co-factor in more than 300 enzyme systems that regulate a number of biological processes, such as protein synthesis, muscle and nerve transmission, neuromuscular conduction, and signal transduction. It is also involved in the cardiovascular system via the regulation of vascular tone, heart rhythm, endothelial function, and platelet-activated thrombosis [1,2,3,4,5]. An insufficient Mg intake and hypomagnesemia are associated with inflammation, oxidative stress, and metabolic derangements, such as diabetes mellitus (DM) and dyslipidemia [5,6,7,8], all of which contribute to the development of cardiovascular disease. It is well known that cardiovascular mortality is 10–30-fold higher in dialysis patients than in the general population [9]. Recent clinical studies reported the negative impact of hypomagnesemia in patients with chronic kidney disease (CKD). The potentially protective role of Mg in this population has been attracting increasing attention. We herein review clinical studies that examined the effects of serum Mg levels on cardiovascular disease and mortality and discuss Mg-related interventions in CKD patients.

Mg and the kidney

The human body stores approximately 25 g of Mg: 66% of this is in bone, 33% in intracellular spaces, and 1% in extracellular spaces [5, 10]. Serum Mg levels in healthy subjects are maintained within a narrow range primarily by the balance between intestinal absorption and renal excretion. In the kidney, most Mg filtered by the glomeruli is immediately reabsorbed and only 3–5% is excreted in the urine [5]. Reabsorption occurs in the ascending limb of Henle’s loop mainly via paracellular transport, and transcellular transport in the distal convoluted segment contributes to maintaining the regulation of Mg. Renal tubular reabsorption of Mg is increased by extracellular volume contraction, hypomagnesemia, and high parathyroid hormone (PTH) levels [10].

Several observational studies identified hypomagnesemia as a predictor of a decline in renal function [11,12,13,14]. Tin et al. evaluated the risk of renal function loss in association with serum Mg levels in 13,226 patients during a median follow-up period of 21 years [13]. In a multivariate analysis adjusted for demographics, baseline renal function, nutrition markers, and comorbidities, patients with low serum Mg levels ≤ 1.70 mg/dL (0.70 mmol/L) showed a 58% higher hazard ratio (HR) for incident CKD and a 139% higher HR for end-stage renal disease (ESRD) than those with the highest quartile of serum Mg levels (2.19–2.80 mg/dL [0.90–1.15 mmol/L]). Sakaguchi et al. demonstrated a significant interaction between serum Mg and P levels on CKD progression [14]. Among 311 non-diabetic CKD patients, those in the lower Mg and higher P group were at a 2.07-fold risk for incident ESRD compared with those in the higher Mg and higher P group. The mechanisms contributing to the relationship between hypomagnesemia and renal function loss have not yet been elucidated in detail, but endothelial dysfunction, inflammation, vascular calcification, DM, insulin resistance, hyperaldosteronism, and pro-thrombotic effects may be involved [13, 15]. Lower dietary Mg intake may also induce renal function loss [16].

Mg and dialysis therapy

Dialysate Mg concentrations are one of the main factors influencing the Mg balance and serum Mg levels in dialysis patients. Mg easily crosses the hemodialyzer membrane and peritoneal membrane, and the amount of Mg elimination depends on its concentration gradient between serum and dialysate. A small amount of Mg is also removed by ultrafiltration. Actually, hypertonic dialysate use has been associated with hypomagnesemia in patients treated with peritoneal dialysis (PD) [24]. Dialysate Mg concentrations have changed over time. Until the 1980s, hemodialysis (HD) dialysate with a Mg concentration of 0.75 mmol/L was commonly used, while that with a lower concentration of 0.5 mmol/L is now widely used. In PD, dialysate Mg concentrations have changed from 0.75 to 0.25 mmol/L. These changes may be attributable to concerns regarding the suggestion by some studies of the adverse influence of hypermagnesemia on renal osteodystrophy [25], uremic pruritus [26], and visceral calcification [27] and the introduction of Mg-containing phosphate binders. Serum Mg levels in dialysis patients have been decreased by the changes of dialysate Mg concentrations, and hypomagnesemia rather than hypermagnesemia is now becoming an issue of interest due to its potent harmful influence. Hypomagnesemia is more common in PD patients than in HD patients because of lower dialysate Mg concentrations as well as the continuous nature of PD therapy.

Dietary Mg intake is another factor that influences serum Mg levels [28]. Dietary Mg is mainly absorbed in the small intestine. The active form of vitamin D has been shown to stimulate intestinal Mg absorption [5], which may partly explain depressed Mg absorption reported in CKD patients with a deficiency in active vitamin D [29]. Schmulen et al. previously showed that the administration of vitamin D receptor activators enhanced intestinal Mg absorption in CKD patients [30]. Mg-rich foods include green vegetables, peas, beans, nuts, seeds, and some fish [28], which are often restricted to avoid hyperkalemia and hyperphosphatemia. Therefore, dietary Mg intake may be insufficient, particularly in dialysis patients, as described by Luis et al. [31]. Serum Mg levels may be used as nutritional markers in dialysis patients because they correlate with serum albumin levels [24, 32,33,34,35,36], body mass index [24, 32], normalized protein catabolic rate [32, 34, 36], muscle mass [32] and strength [37], and subjective global assessment scores [32]. Of interest, the use of a low Mg PD dialysate induced a decrease in serum albumin levels [38].

In order to treat the complications that occur during long-term CKD, a number of drugs, such as diuretics, antibiotics, chemotherapeutic agents, β-blockers, and proton-pump inhibitors, are often used and may induce hypomagnesemia [5].

The relationship between serum Mg levels and mortality in CKD patients is shown in Table 2 [12, 33,34,35, 69,70,71,72]. Van Laecke et al. found that adjusted HR for all-cause mortality decreased by 7% with a 0.1-mg/dL (0.04 mmol/L) increase in serum Mg levels in non-dialysis CKD patients [12]. In the study by Cai et al. which included 253 incident PD patients, all-cause and cardiovascular mortalities were significantly lower in the high-serum-Mg group than in the low-Mg group [35]. Yang et al. examined 10,692 incident PD patients in the USA and found a significant association between hypomagnesemia and hospitalization [72]. However, hypomagnesemia was not an independent predictor of all-cause death after adjustments for laboratory variables. In HD patients, Ishimura et al. were the first to report an independent relationship between hypomagnesemia and all-cause mortality [73]. This study included 515 patients, and the mortality risk decreased by 52% with a 1-mg/dL increase in serum Mg levels. Recently, similar findings have been increasingly reported in large-scale studies [33, 34, 69,70,71]. Sakaguchi et al. examined this relationship using the Japanese National Registry data [69]. Although the follow-up period was limited to 1 year, the lowest Mg sextile group (serum Mg levels < 2.3 mg/dL [0.95 mmol/L]) showed the highest all-cause and non-cardiovascular mortality risks, whereas the second highest Mg sextile (2.8–3.1 mg/dL [1.15–1.28 mmol/L]) showed the lowest mortality risk. It was notable that the second highest all-cause mortality risk and highest cardiovascular mortality risk were found in the highest Mg sextile (≥ 3.1 mg/dL [1.28 mmol/L]). Consistent with these findings, a restricted cubic spline analysis showed that the shape of the fully adjusted relationship between serum Mg levels and all-cause mortality was J shaped. Kurita et al. also employed a restricted cubic spline analysis in 2165 Japanese patients and found a similar curve for the relationship between serum Mg levels and all-cause mortality [70]. In Europe, de Roji van Zuijdewijn et al. demonstrated that lower serum Mg levels were associated with a high risk of all-cause and cardiovascular death as well as sudden death [71]. In these three studies [69,70,71], the relationship between hypomagnesemia and the mortality risk remained significant after the full adjustments. However, the findings from the USA [33, 34] were different. In Lacson’s study [33], a linear decline was observed in the risk of all-cause death adjusted for case-mix variables (see Table 2) from the lowest to the highest serum Mg category, with the best survival in the category with the highest serum Mg levels (> 3.04 mg/dL [1.25 mmol/L]). However, the relationship between hypomagnesemia and mortality was not significant after additional adjustments for laboratory variables. Similarly, Li et al. reported that time-varying serum Mg levels did not predict the death in incident HD patients after adjustment for laboratory variables [34].

Thus, a relationship exists between hypomagnesemia and mortality, even after full adjustment for laboratory variables in patients from Asia and Europe [35, 69,70,71], but not in those from the USA [33, 34, 72]. Based on these results, it seems that patient’s race or region may be involved in susceptibility to the harmful effects of hypomagnesemia. There may be another opinion that in the studies from the USA with the short dialysis duration (Table 2), the prognostic impact of hypomagnesemia might be confounded or diluted by residual renal function. Residual renal function is considered to be beneficial for the prognosis and has a negative impact on Mg balance even in HD patients. The median of HD duration in Lacson’s study [33] was comparable to that in de Roji van Zuijdewijn’s study [71]. Both Cai’s [35] and Yang’s study [72] included incident PD patients. However, hypomagnesemia was an independent predictor of mortality only in Cai’s (from China) and de Roji van Zuijdewijn’s study (from Europe).

Mg-related interventions in CKD/ESRD patients

There are two methods to increase serum Mg levels: increasing dialysate Mg concentrations and Mg supplementation. However, evidence from interventional studies to prove the favorable effects of Mg on cardiovascular disease and mortality is limited, which is not in proportion to the increasing interest in Mg. These interventions should be employed with careful monitoring of serum Mg levels to avoid hypermagnesemia.

Dialysates with higher Mg concentrations

Dialysates with higher Mg concentrations are feasible and effective for increasing serum Mg levels. In Nilsson’s study including 22 HD patients who had been treated with 0.75 mmol/L-Mg dialysate, 12 were assigned to 0.2 mmol/L dialysate and 10 continued to use 0.75 mmol/L dialysate [58]. Four months later, the former patients showed a significant decrease in serum Mg levels from 2.71 ± 0.55 mg/dL (1.11 ± 0.23 mmol/L) to 2.26 ± 0.54 mg/dL (0.93 ± 0.22 mmol/L, P < 0.01), whereas the latter did not. Similar findings have been also reported in PD by Ejaz et al. [38]. None of the 33 patients had hypomagnesemia (defined as < 1.52 mg/dL [0.625 mmol/L]) with the use of 0.75 mmol/L-Mg dialysate. After the change to 0.25 mmol/L Mg-dialysate, 21 patients (63.6%) developed hypomagnesemia. This change also resulted in lower serum albumin levels in those with than in those without hypomagnesemia (2.5 ± 0.12 g/dL vs. 3.2 ± 0.12 g/dL, P < 0.01). Regardless of these findings, the effects of dialysates with higher Mg concentrations on cardiovascular disease and mortality have not yet been examined. Dialysate Mg-related clinical trials are of interest and need to be conducted in the future.

Mg-containing phosphate binders

It is important to control hyperphosphatemia, which leads to cardiovascular calcification and increased morbidity and mortality in CKD patients [74]. Mg is contained in some phosphate binders and its affinity for P is weaker than that of Al and Ca. Since the mid-1980s, magnesium hydroxide was used to replace Al-containing phosphate binders but caused diarrhea and mild hyperkalemia [75]. Magnesium carbonate effectively controlled serum P levels with less adverse effects [75]. However, Mg-containing phosphate binders have not been widely used because of concerns regarding hypermagnesemia. In 2010, a randomized controlled trial (RCT), the CALMAG study, which compared the efficacy of calcium acetate/magnesium carbonate and sevelamer hydrochloride in HD patients, was reported [59]. At week 25, mean reductions in serum P from baseline in the calcium acetate/magnesium carbonate group and sevelamer group were similar. Serum Mg levels in the former group significantly increased from baseline (0.73 ± 0.56 mg/dL [0.30 ± 0.23 mmol/L]), whereas a slight increase was observed in the latter group (0.10 ± 0.36 mg/dL [0.04 ± 0.15 mmol/L]). Gastrointestinal adverse events occurred more frequently in the sevelamer group (23.6 vs. 13.6%). The authors concluded that magnesium carbonate was a tolerable and effective agent in the treatment of hyperphosphatemia.

A few interventional studies have examined the effects of Mg-containing phosphate binders on cardiovascular lesions, as shown in Table 3 [76, 77]. Furthermore, their effects on mortality currently remain unknown. Tzanakis et al. randomly assigned 59 HD patients to calcium acetate or calcium acetate/magnesium carbonate for 12 months [77]. At the end of the study, the number of patients with improved carotid IMT was significantly higher in the Mg-containing phosphate binder group than in the Ca-containing binder group (P = 0.04). Turgut et al. also showed the beneficial effects of Mg supplementation [76]. However, these findings appeared to be inconclusive because of the relatively small sample size as well as the accuracy and reproducibility of the evaluation methods.

In a sub-analysis of the aforementioned Japanese National Registry data [69], Sakaguchi et al. reported that the mortality risk of HD patients with hyperphosphatemia was attenuated with increases in serum Mg levels [78]. If large-scale RCTs successfully show the benefits of Mg-containing phosphate binders for cardiovascular disease and mortality, these drugs may be widely used in the control of hyperphosphatemia.

Mg-containing laxatives

The prevalence of constipation requiring laxative therapy is high in ESRD patients [79, 80]. Mg-containing laxatives may be used to concurrently treat constipation and hypomagnesemia. However, these drugs should be used carefully. Serum Mg levels were increased to approximately 10 mg/dL (4.11 mmol/L) by magnesium oxide administered at 3 g/day in dialysis patients, resulting in muscle paresis or impaired consciousness [81, 82]. Toprak et al. conducted a RCT including 128 pre-diabetic patients with hypomagnesemia (< 1.8 mg/dL [0.74 mmol/L] in males and < 1.9 mg/dL [0.78 mmol/L] in females) and mild to moderate CKD (estimated GFR 30–60 mL/min/1.73 m2) [83]. Patients were assigned to magnesium oxide or placebo for 3 months. Magnesium oxide was administered at 613.2 mg/day and serum Mg levels increased from 1.70 ± 0.13 mg/dL (0.70 ± 0.05 mmol/L) to 1.91 ± 0.22 mg/dL (0.79 ± 0.09 mmol/L). At the end of this study, insulin resistance, glycemic control, and uric acid levels were better in the former than in the latter patient group. These improvements in metabolic indices were accompanied by an increase in not only serum Mg, but also albumin levels.

Sevelamer

Sevelamer is a Ca-free, Mg-free, non-absorbable anion exchange resin that is used to control hyperphosphatemia. There are two salts of sevelamer: sevelamer hydrochloride and sevelamer carbonate. This drug has been reported to increase serum Mg levels. Mitsopoulos et al. found that the mean serum Mg levels significantly increased from 2.75 mg/dL (1.13 mmol/L) to 2.90 mg/dL (1.19 mmol/L) during an 8-week treatment with sevelamer [84]. Chertow et al. also reported a significant increase in serum Mg levels induced by sevelamer [85]. In addition, two cross-sectional studies showed an independent relationship between sevelamer and higher serum Mg levels [36, 86]. It seems plausible to speculate that this effect of sevelamer depends on its adsorptive action on some substances other than P. Free fatty acids in the intestinal lumen may combine with Mg to form non-absorbable soaps. Therefore, Mitsopoulos et al. speculated that sevelamer binds biliary salts, thereby increasing the quantity of free Mg available for intestinal absorption [84]. On the other hand, Nagano et al. reported the contribution of magnesium stearate, which is included as a pharmaceutical excipient in phosphate binders, to increases in serum Mg levels [87].

Sevelamer has been reported to exert favorable effects on inflammation, oxidative stress, glucose metabolism, lipid profiles, and cardiovascular disease [88, 89], similar to Mg supplementation. Although the precise mechanisms responsible for these effects of sevelamer have not yet been elucidated, the increases in serum Mg levels induced by the drug itself may be included in these mechanisms.

Conclusions

In the clinical practice of dialysis therapy, concerns need to shift from hypermagnesemia to hypomagnesemia. Dialysis patients, particularly those treated with PD, are exposed to the risk of hypomagnesemia because of the use of dialysates with low Mg concentrations as well as decreased intake/absorption and the adverse effects of some drugs. Observational studies have almost consistently indicated that hypomagnesemia is associated with cardiovascular disease and mortality in CKD. However, this relationship may depend on a patient’s race or region. Dialysates with higher Mg concentrations and some drugs including phosphate binders are useful for increasing serum Mg levels, but few interventional studies have examined the benefits of the correction of hypomagnesemia. Further studies are required in order to establish the efficacy of Mg supplementation in CKD patients. In addition, it is important to establish the harmless upper limit of serum Mg levels.

Abbreviations

BMP:

Bone morphogenetic protein

CKD:

Chronic kidney disease

CPP:

Calciprotein particle

DM:

Diabetes mellitus

ESRD:

End-stage renal disease

GFR:

Glomerular filtration rate

HD:

Hemodialysis

HR:

Hazard ratio

IMT:

Intima-media thickness

PD:

Peritoneal dialysis

PTH:

Parathyroid hormone

RCT:

Randomized controlled trial

VSMC:

Vascular smooth muscle cell

References

1.

Altura BM, Altura BT. New perspectives on the role of magnesium in the pathophysiology of the cardiovascular system. I Clinical aspects Magnesium. 1985;4:226–44.

Corresponding author

Ethics declarations

Ethics approval and consent to participate

Consent for publication

Competing interests

The author declares no competing interest.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.